CergenX achieves CE Mark for pioneering AI technology designed to transform newborn brain assessment

Irish medtech company reaches major regulatory milestone for AI-powered technology providing rapid, objective insights into newborn brain activity

CORK, Ireland — 

Sept 1 2026 – CergenX, an Irish medtech company transforming early brain health through AI-powered clinical insights, has announced that its first product, Wave, has achieved CE Mark certification under EU MDR 2017/745. Wave uses EEG and artificial intelligence to provide clinicians with rapid, objective insights into newborn brain activity and abnormalities associated with brain injury.

The certification is a major milestone for CergenX, enabling the company to commercialise Wave across the European market and marking an important step towards making expert neonatal brain assessment more widely accessible.

Sign up for Blog Updates